210 related articles for article (PubMed ID: 26623653)
21. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.
Yu C; Rahmani M; Conrad D; Subler M; Dent P; Grant S
Blood; 2003 Nov; 102(10):3765-74. PubMed ID: 12893773
[TBL] [Abstract][Full Text] [Related]
22. Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat.
Yao L; Mustafa N; Tan EC; Poulsen A; Singh P; Duong-Thi MD; Lee JXT; Ramanujulu PM; Chng WJ; Yen JJY; Ohlson S; Dymock BW
J Med Chem; 2017 Oct; 60(20):8336-8357. PubMed ID: 28953386
[TBL] [Abstract][Full Text] [Related]
23. IL-6 stimulation of DNA replication is JAK1/2 mediated in cross-talk with hyperactivated ERK1/2 signaling.
Subotički T; Mitrović Ajtić O; Beleslin-Čokić BB; Bjelica S; Djikić D; Diklić M; Leković D; Gotić M; Santibanez JF; Noguchi CT; Čokić VP
Cell Biol Int; 2019 Feb; 43(2):192-206. PubMed ID: 30571852
[TBL] [Abstract][Full Text] [Related]
24. Role of additional novel therapies in myeloproliferative neoplasms.
Fiskus W; Ganguly S; Kambhampati S; Bhalla KN
Hematol Oncol Clin North Am; 2012 Oct; 26(5):959-80. PubMed ID: 23009932
[TBL] [Abstract][Full Text] [Related]
25. mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.
Bogani C; Bartalucci N; Martinelli S; Tozzi L; Guglielmelli P; Bosi A; Vannucchi AM;
PLoS One; 2013; 8(1):e54826. PubMed ID: 23382981
[TBL] [Abstract][Full Text] [Related]
26. Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?
Pardanani A; Tefferi A
Leuk Lymphoma; 2014 Dec; 55(12):2706-11. PubMed ID: 25520049
[TBL] [Abstract][Full Text] [Related]
27. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML.
Karjalainen R; Pemovska T; Popa M; Liu M; Javarappa KK; Majumder MM; Yadav B; Tamborero D; Tang J; Bychkov D; Kontro M; Parsons A; Suvela M; Mayoral Safont M; Porkka K; Aittokallio T; Kallioniemi O; McCormack E; Gjertsen BT; Wennerberg K; Knowles J; Heckman CA
Blood; 2017 Aug; 130(6):789-802. PubMed ID: 28619982
[TBL] [Abstract][Full Text] [Related]
28. The synergistic effect of BCR signaling inhibitors combined with an HDAC inhibitor on cell death in a mantle cell lymphoma cell line.
Hagiwara K; Kunishima S; Iida H; Miyata Y; Naoe T; Nagai H
Apoptosis; 2015 Jul; 20(7):975-85. PubMed ID: 25835755
[TBL] [Abstract][Full Text] [Related]
29. Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms.
Bose P; Verstovsek S
Expert Opin Investig Drugs; 2016 Dec; 25(12):1393-1403. PubMed ID: 27756180
[TBL] [Abstract][Full Text] [Related]
30. IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms.
de Melo Campos P; Machado-Neto JA; Eide CA; Savage SL; Scopim-Ribeiro R; da Silva Souza Duarte A; Favaro P; Lorand-Metze I; Costa FF; Tognon CE; Druker BJ; Olalla Saad ST; Traina F
Oncotarget; 2016 Feb; 7(6):6948-59. PubMed ID: 26755644
[TBL] [Abstract][Full Text] [Related]
31. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
Hobbs GS; Rozelle S; Mullally A
Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
[TBL] [Abstract][Full Text] [Related]
32. Targeting the PI3K pathway in myeloproliferative neoplasms.
Gerds AT; Bartalucci N; Assad A; Yacoub A
Expert Rev Anticancer Ther; 2022 Aug; 22(8):835-843. PubMed ID: 35763287
[TBL] [Abstract][Full Text] [Related]
33. Vorinostat, a HDAC inhibitor, showed anti-osteoarthritic activities through inhibition of iNOS and MMP expression, p38 and ERK phosphorylation and blocking NF-κB nuclear translocation.
Zhong HM; Ding QH; Chen WP; Luo RB
Int Immunopharmacol; 2013 Oct; 17(2):329-35. PubMed ID: 23856614
[TBL] [Abstract][Full Text] [Related]
34. Mechanism for neurotropic action of vorinostat, a pan histone deacetylase inhibitor.
Shukla S; Shariat-Madar Z; Walker LA; Tekwani BL
Mol Cell Neurosci; 2016 Dec; 77():11-20. PubMed ID: 27678157
[TBL] [Abstract][Full Text] [Related]
35. CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.
Meyer SC; Keller MD; Chiu S; Koppikar P; Guryanova OA; Rapaport F; Xu K; Manova K; Pankov D; O'Reilly RJ; Kleppe M; McKenney AS; Shih AH; Shank K; Ahn J; Papalexi E; Spitzer B; Socci N; Viale A; Mandon E; Ebel N; Andraos R; Rubert J; Dammassa E; Romanet V; Dölemeyer A; Zender M; Heinlein M; Rampal R; Weinberg RS; Hoffman R; Sellers WR; Hofmann F; Murakami M; Baffert F; Gaul C; Radimerski T; Levine RL
Cancer Cell; 2015 Jul; 28(1):15-28. PubMed ID: 26175413
[TBL] [Abstract][Full Text] [Related]
36. The phosphatidylinositol 3-kinases (PI3K) inhibitor GS-1101 synergistically potentiates histone deacetylase inhibitor-induced proliferation inhibition and apoptosis through the inactivation of PI3K and extracellular signal-regulated kinase pathways.
Bodo J; Zhao X; Sharma A; Hill BT; Portell CA; Lannutti BJ; Almasan A; Hsi ED
Br J Haematol; 2013 Oct; 163(1):72-80. PubMed ID: 23889282
[TBL] [Abstract][Full Text] [Related]
37. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C
Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343
[TBL] [Abstract][Full Text] [Related]
38. Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms.
Kleppe M; Koche R; Zou L; van Galen P; Hill CE; Dong L; De Groote S; Papalexi E; Hanasoge Somasundara AV; Cordner K; Keller M; Farnoud N; Medina J; McGovern E; Reyes J; Roberts J; Witkin M; Rapaport F; Teruya-Feldstein J; Qi J; Rampal R; Bernstein BE; Bradner JE; Levine RL
Cancer Cell; 2018 Jan; 33(1):29-43.e7. PubMed ID: 29249691
[TBL] [Abstract][Full Text] [Related]
39. HDAC8 overexpression in mesenchymal stromal cells from JAK2+ myeloproliferative neoplasms: a new therapeutic target?
Ramos TL; Sánchez-Abarca LI; Redondo A; Hernández-Hernández Á; Almeida AM; Puig N; Rodríguez C; Ortega R; Preciado S; Rico A; Muntión S; Porras JRG; Del Cañizo C; Sánchez-Guijo F
Oncotarget; 2017 Apr; 8(17):28187-28202. PubMed ID: 28390197
[TBL] [Abstract][Full Text] [Related]
40. Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemia.
Okabe S; Tauchi T; Kimura S; Maekawa T; Kitahara T; Tanaka Y; Ohyashiki K
PLoS One; 2014; 9(2):e89080. PubMed ID: 24586514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
